Core Insights - The company reported a total operating revenue of 2.498 billion yuan for the year 2025, representing a year-on-year growth of 28.23% [1] - The sales revenue of the company's core product, Toripalimab injection (brand name: Tuoyi), in the domestic market saw a significant increase of approximately 37.72% year-on-year [1] - The net profit attributable to the parent company's owners was -874 million yuan, an improvement from -1.281 billion yuan in the same period last year [1]

Core Viewpoint - Junshi Biosciences (01877) has seen a stock price increase of over 5%, currently trading at 21.8 HKD, with a transaction volume of 39.91 million HKD. The company announced expectations for significant revenue growth and reduced losses for the fiscal year 2025 [1]. Group 1: Financial Projections - The company anticipates achieving an annual revenue of approximately 2.5 billion RMB in 2025, representing a year-on-year growth of about 28.32% [1]. - Expected R&D expenses for 2025 are projected to be around 1.353 billion RMB, reflecting a year-on-year increase of approximately 6.10% [1]. - The net loss attributable to shareholders for 2025 is estimated to be around 873 million RMB, which is a reduction of about 31.85% compared to the previous year [1]. - After excluding the impact of share-based payments, the net loss attributable to shareholders is expected to be approximately 799 million RMB, indicating a year-on-year decrease of about 37.62% [1]. - The net loss attributable to shareholders, after excluding non-recurring gains and losses, is projected to be around 985 million RMB, which is a reduction of approximately 23.64% year-on-year [1]. Group 2: Product Performance - The company's revenue growth during the reporting period is primarily driven by increased sales of commercialized drugs compared to the previous year [2]. - The core product, Toripalimab injection (brand name: Tuoyi), has seen a significant increase in sales revenue in the domestic market year-on-year [2]. - As of the announcement date, Tuoyi has been included in the national medical insurance catalog for all 12 approved indications in mainland China, making it the only anti-PD-1 monoclonal antibody drug in the catalog for the treatment of renal cancer, triple-negative breast cancer, and melanoma [2].

Core Viewpoint - Junshi Biosciences (01877) expects to achieve approximately CNY 2.5 billion in revenue for the fiscal year 2025, representing a year-on-year growth of about 28.32% [1] Financial Performance - The projected R&D expenses for 2025 are approximately CNY 1.353 billion, reflecting a year-on-year increase of about 6.10% [1] - The expected net loss attributable to the parent company for 2025 is around CNY 873 million, which is a reduction of approximately 31.85% compared to the previous year [1] - After excluding the impact of share-based payments, the net loss is projected to be about CNY 799 million, a decrease of approximately 37.62% year-on-year [1] - The net loss attributable to the parent company, excluding non-recurring gains and losses, is expected to be around CNY 985 million, down by about 23.64% year-on-year [1] - After excluding the impact of share-based payments and non-recurring gains and losses, the net loss is projected to be approximately CNY 911 million, a reduction of about 29.37% year-on-year [1] Product and Market Development - The increase in revenue is primarily due to the growth in sales of commercialized drugs, particularly the core product Toripalimab injection (brand name: Tuoyi), which saw significant sales growth in the domestic market [1] - As of the date of this announcement, Tuoyi has been approved for 12 indications in mainland China and is the only anti-PD-1 monoclonal antibody included in the national medical insurance catalog for the treatment of renal cancer, triple-negative breast cancer, and melanoma [1] - The company continues to expand its global commercialization network, with Toripalimab approved in over 40 countries and regions, including mainland China, Hong Kong, the United States, the European Union, and others [2] Strategic Initiatives - Despite the expected net loss for 2025, the company has significantly narrowed its loss compared to the previous year, attributed to the implementation of the "quality improvement and efficiency enhancement" action plan [2] - The company has improved its commercialization capabilities while strengthening cost control and resource focus [2] - The company is advancing multiple innovative drugs with international market competitiveness, including JS207 (a PD-1/VEGF dual antibody), JS212 (an EGFR/HER3 ADC), and JS213 (a PD-1/IL-2 fusion protein), which are in various stages of clinical trials [2] - JS207 is currently in Phase II clinical research, exploring combinations with chemotherapy, monoclonal antibodies, and ADCs across multiple tumor types [2] - The company aims to accelerate pipeline development and push more advantageous products and indications into the registration clinical trial phase [2]

Core Viewpoint - Shanghai Junshi Biosciences Co., Ltd. has successfully included two of its products, Toripalimab Injection (brand name: Tuoyi) and Engrelistat Injection (brand name: Junshida), in the National Medical Insurance Catalog (2025) under Category B, effective from January 1, 2026 [1][2]. Group 1: Product Information - Toripalimab Injection is the first domestically approved PD-1 monoclonal antibody in China, with 12 indications approved for listing in the National Medical Insurance Catalog, including treatments for renal cancer, triple-negative breast cancer, and melanoma [2][4]. - Engrelistat Injection is a domestically developed PCSK9-targeting drug, newly included in the National Medical Insurance Catalog, specifically for patients intolerant to statins [5][6]. Group 2: Market Impact - The inclusion of these products in the National Medical Insurance Catalog reflects the recognition of their clinical value and innovation by the National Healthcare Security Administration, which supports local innovative pharmaceutical companies [6]. - The listing of all commercialized products in the National Medical Insurance Catalog is expected to enhance affordability and accessibility for patients, thereby promoting market expansion and increasing sales scale for the company [6].

Core Viewpoint - Shanghai Junshi Biosciences Co., Ltd. announced the inclusion of its products Tuoyi (Tremelimumab injection) and Junshida (Angrezi monoclonal antibody injection) in the National Medical Insurance Directory, effective January 1, 2026, highlighting the recognition of their clinical value and innovation by the National Healthcare Security Administration [1][6]. Group 1: Product Information - Tuoyi (Tremelimumab injection) has received approval for 12 indications, all of which are now included in the National Medical Insurance Directory, making it the only PD-1 monoclonal antibody drug listed for the treatment of renal cancer, triple-negative breast cancer, and melanoma [1][2]. - Junshida (Angrezi monoclonal antibody injection) is the only domestic PCSK9-targeted drug included in the new insurance directory for patients intolerant to statins, marking its first inclusion [1][5]. Group 2: Market Impact - The inclusion of both drugs in the National Medical Insurance Directory is expected to enhance patient affordability and accessibility, thereby promoting market expansion and increasing sales scale for the company [6]. - The company plans to actively cooperate with the implementation of insurance policies and expand its market coverage to improve patient access to medications [6]. Group 3: Internationalization - Tuoyi has been approved for marketing in multiple countries and regions, including the United States, European Union, and several others, indicating a strong international presence [3].

Core Viewpoint - Junshi Biosciences (01877) announced the addition of two new indications for its product Toripalimab (brand name: Tuoyi) and the inclusion of its product Engrezt (brand name: Junshida) in the National Medical Insurance Directory, effective January 1, 2026 [1] Group 1 - The product Toripalimab has received approval for 12 indications in mainland China, all of which are included in the National Medical Insurance Directory, making it the only anti-PD-1 monoclonal antibody in the directory for the treatment of renal cancer, triple-negative breast cancer, and melanoma [1] - Engrezt is newly included in the directory and is the only domestic PCSK9-targeted drug for patients intolerant to statins in the updated list [1]

Core Viewpoint - Junshi Biosciences (01877.HK) announced that its products, Toripalimab Injection (brand name: Tuoyi, product code: JS001) and Engreitzumab Injection (brand name: Junshida, product code: JS002), have been included in the National Medical Insurance Catalog (2025) under Category B, effective January 1, 2026 [1] Group 1 - The inclusion of Toripalimab's two new indications and Junshida in the National Medical Insurance Catalog reflects the National Healthcare Security Administration's recognition of the clinical value, patient benefits, and innovation of these drugs [1] - Toripalimab is the only anti-PD-1 monoclonal antibody in the catalog approved for treating renal cancer, triple-negative breast cancer, and melanoma, with all 12 approved indications included [1] - Junshida is the first domestic PCSK9-targeted drug included in the new catalog for patients intolerant to statins [1] Group 2 - All four commercialized products of the company, including Tuoyi, Adalimumab Injection (brand name: Junmaikang, product code: UBP1211), Dexamethasone Hydrochloride Tablets (brand name: Mindewi, product code: VV116/JT001), and Junshida, are now part of the National Medical Insurance Catalog [2] - The inclusion in the catalog is expected to enhance affordability and accessibility for patients, promoting market expansion and increasing sales scale, positively impacting the company's long-term operational development [2] - The company will actively cooperate to implement the medical insurance policy, continue to advance hospital access, and expand coverage in core and broader markets to improve patient access to medications [2]

Core Insights - Junshi Biosciences (君实生物) announced the inclusion of two new indications for its product Toripalimab injection (brand name: Tuoyi) and the successful addition of its product Engreztinib injection (brand name: Junshida) to the National Medical Insurance Catalog for 2025 [1] Group 1: Product Developments - Toripalimab has now been approved for all 12 indications in mainland China and is the only anti-PD-1 monoclonal antibody in the catalog for the treatment of renal cancer, triple-negative breast cancer, and melanoma [1] - Junshida is newly included in the catalog and is the only domestic PCSK9-targeted drug for patients intolerant to statins in the updated list [1] Group 2: Market Position - As of the announcement date, four commercialized products from Junshi Biosciences, including Tuoyi, Adalimumab injection (brand name: Junmaikang), Dexamethasone Hydrochloride tablets (brand name: Mindewi), and Junshida, have been included in the National Medical Insurance Catalog [1]

Core Viewpoint - Junshi Biosciences (688180.SH) announced that its products, Toripalimab injection (brand name: Tuoyi) and Engreztinib injection (brand name: Junshida), have been included in the Category B of the National Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug List (2025) [1] Group 1 - Toripalimab has been approved for 12 indications in mainland China and is the only anti-PD-1 monoclonal antibody included in the national medical insurance directory for the treatment of renal cancer, triple-negative breast cancer, and melanoma [1] - Engreztinib is newly included in the directory and is the only domestic PCSK9-targeted drug for patients intolerant to statins [1] - The inclusion of these drugs reflects the recognition by the National Healthcare Security Administration, which will enhance patient affordability and accessibility of medications, thereby promoting the commercialization and sales growth of these products [1]

Core Insights - The article highlights the significant impact of domestic PD-1 inhibitors on reducing cancer treatment costs, leading to a release of previously constrained consumer demand [1] - It emphasizes the evolution of Chinese innovative pharmaceutical companies from imitation to original innovation, particularly in the field of cancer treatment [1][2] Company Development - Junshi Biosciences, as a representative of the thriving domestic innovative pharmaceutical sector, has made notable strides since its establishment in 2012, culminating in the launch of its PD-1 monoclonal antibody, Tuoyi, in 2018 [2][3] - Tuoyi has received approval for 12 indications, with 10 included in the national medical insurance catalog, significantly alleviating patient financial burdens [7] Market Dynamics - The competitive landscape has evolved with the emergence of "PD-1 Four Dragons," including Junshi Biosciences, Innovent Biologics, Hengrui Medicine, and BeiGene, marking PD-1 as a hot innovation track [3][4] - The industry is actively pursuing the development of next-generation immunotherapy drugs to address unmet clinical needs, with Junshi Biosciences allocating a significant portion of its recent financing for this purpose [4][5] Pricing and Accessibility - Junshi's Tuoyi was initially priced at less than one-third of similar imported products, making it one of the lowest-priced PD-1 drugs globally [6] - The company is focused on balancing accessibility and commercialization, as the Chinese innovative drug payment environment undergoes systemic reforms [7][8] International Expansion - Junshi Biosciences is exploring various international market entry strategies, including licensing, joint ventures, and independent commercialization, with a global network covering over 80 countries [10][11] - The company is actively pursuing partnerships to enhance its drug pipeline and expedite the approval process for its products in international markets [10][11] Future Outlook - The innovative drug industry is transitioning from a focus on "life-saving necessities" to "long-term health management services," driven by an aging population and increased health awareness [13] - Junshi Biosciences aims to contribute to the establishment of a globally competitive biopharmaceutical innovation system, emphasizing the importance of clinical efficacy, affordability, and user convenience in redefining the consumption value of innovative drugs [12][13][16]